Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Net Cash Flow (2016 - 2025)

Anaptysbio's Net Cash Flow history spans 10 years, with the latest figure at $128.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 287.39% year-over-year to $128.4 million; the TTM value through Dec 2025 reached $115.1 million, up 32.14%, while the annual FY2025 figure was $115.1 million, 32.14% up from the prior year.
  • Net Cash Flow reached $128.4 million in Q4 2025 per ANAB's latest filing, up from $65.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $159.3 million in Q4 2021 to a low of -$329.3 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$616000.0, with a median of $11.2 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: tumbled 1077.43% in 2022, then soared 1443.96% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $159.3 million in 2021, then crashed by 91.99% to $12.8 million in 2022, then decreased by 24.22% to $9.7 million in 2023, then plummeted by 808.39% to -$68.5 million in 2024, then surged by 287.39% to $128.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Net Cash Flow are $128.4 million (Q4 2025), $65.5 million (Q3 2025), and -$54.3 million (Q2 2025).